Concomitant experiments within our previous clinical phase I/II NK cell study (42) demonstrated that the NKG2D-dependent cytotoxicity against resistant neuroblastoma cells was strongly affected by immunosuppressing NKG2DLs, as one of multiple strategies to escape from immune-mediated eradication. The gene discussed is KLRK1; the disease is neuroblastoma.